Studies have shown that
sulforaphane (SFN) has potent anti-inflammatory and
free radical scavenging effects on
obesity and associated disorder such as diabetes,
polycystic ovary syndrome, and
metabolic syndrome.
fractalkine (CX3CL1) and its receptor, CX3CR1, play an important role in muscle metabolism by improving
insulin-sensitizing effects. Here, in this study we examined the SFN effect on CX3CL1 and its receptor, CX3CR1, in C2C12 myotubes in
palmitic acid (PA)-induced oxidative stress and
inflammation. The results showed that PA (750 μM) evoked lipotoxicity as a reduction in cell viability, increased
IL-6 and TNF-α expression, and enhanced
reactive oxygen species (ROS). However, SFN pretreatment attenuated the levels of,
IL-6 and TNF-α in C2C12 myotubes exposure to PA. Moreover, SFN pretreatment up-regulated nuclear factor erythroid related factor 2 (Nrf2) /
heme oxygenase-1(HO-1) pathway
protein in C2C12 cells as indicated by a decrease in ROS levels. Interestingly, PA also caused an increase in CX3CL1 and CX3CR1 expression that SFN abrogated it. We also found the protective effect of SFN agonist PA-induced lipotoxicity with promotes in UCP3 gene expression in C2C12 cells. Collectively, these findings suggest that SFN hampers the PA-induced
inflammation in C2C12 cells by modulation of the Nrf2/HO-1 pathway and CX3CL1/CX3CR1 axis and may propose a new therapeutic approach to protect against
obesity-associated disorders in skeletal muscle cells.